Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009 (2009), Article ID 101857, 8 pages
http://dx.doi.org/10.1155/2009/101857
Research Article

Activation of PPAR 𝛾 by Rosiglitazone Does Not Negatively Impact Male Sex Steroid Hormones in Diabetic Rats

Department of Anatomy, Physiology and Pharmacology, Auburn University, AL 36849, USA

Received 22 December 2008; Revised 17 March 2009; Accepted 29 April 2009

Academic Editor: Carolyn Komar

Copyright © 2009 Mahmoud Mansour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. M. Komar, “Peroxisome proliferator-activated receptors (PPARs) and ovarian function—implications for regulating steroidogenesis, differentiation, and tissue remodeling,” Reproductive Biology and Endocrinology, vol. 3, article 41, pp. 1–14, 2005. View at Publisher · View at Google Scholar · View at PubMed
  2. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar · View at PubMed
  3. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Google Scholar
  4. S. Gasic, Y. Bodenburg, M. Nagamani, A. Green, and R. J. Urban, “Troglitazone inhibits progesterone production in porcine granulosa cells,” Endocrinology, vol. 139, no. 12, pp. 4962–4966, 1998. View at Google Scholar
  5. L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” Pharmacology & Therapeutics, vol. 110, no. 3, pp. 371–385, 2006. View at Google Scholar
  6. M. Wu, D. S. Melichian, E. Chang, M. Warner-Blankenship, A. K. Ghosh, and J. Varga, “Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-γ,” The American Journal of Pathology, vol. 174, no. 2, pp. 519–533, 2009. View at Publisher · View at Google Scholar · View at PubMed
  7. J. E. Milam, V. G. Keshamouni, S. H. Phan et al., “PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis,” American Journal of Physiology, vol. 294, no. 5, pp. L891–L901, 2008. View at Publisher · View at Google Scholar · View at PubMed
  8. T. Kawai, T. Masaki, S. Doi et al., “PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β,” Laboratory Investigation, vol. 89, no. 1, pp. 47–58, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. S. S. Chung, M. Kim, B.-S. Youn et al., “Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor γ in human skeletal muscle cells,” Molecular and Cellular Biology, vol. 29, no. 1, pp. 20–30, 2009. View at Publisher · View at Google Scholar · View at PubMed
  10. E. Teissier, A. Nohara, G. Chinetti et al., “Peroxisome proliferator-activated receptor α induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-α activation properties,” Circulation Research, vol. 95, no. 12, pp. 1174–1182, 2004. View at Publisher · View at Google Scholar · View at PubMed
  11. P. R. Devchand, O. Ziouzenkova, and J. Plutzky, “Oxidative stress and peroxisome proliferator-activated receptors. Reversing the curse?,” Circulation Research, vol. 95, no. 12, pp. 1137–1139, 2004. View at Publisher · View at Google Scholar · View at PubMed
  12. P. D. Schoppee, J. C. Garmey, and J. D. Veldhuis, “Putative activation of the peroxisome proliferator-activated receptor γ impairs androgen and enhances progesterone biosynthesis in primary cultures of porcine theca cells,” Biology of Reproduction, vol. 66, no. 1, pp. 190–198, 2002. View at Google Scholar
  13. W. Arlt, R. J. Auchus, and W. L. Miller, “Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase,” The Journal of Biological Chemistry, vol. 276, no. 20, pp. 16767–16771, 2001. View at Publisher · View at Google Scholar · View at PubMed
  14. H. Vierhapper, P. Nowontny, and W. Waldhäusl, “Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone,” Metabolism: Clinical and Experimental, vol. 52, no. 2, pp. 230–232, 2003. View at Publisher · View at Google Scholar · View at PubMed
  15. G. L. Rubin, J. H. Duong, C. D. Clyne et al., “Ligands for the peroxisomal proliferator-activated receptor γ and the retinoid X receptor inhibit aromatase cytochrome P450 (CYP19) expression mediated by promoter II in human breast adipose,” Endocrinology, vol. 143, no. 8, pp. 2863–2871, 2002. View at Publisher · View at Google Scholar
  16. S. Gasic, M. Nagamani, A. Green, and R. J. Urban, “Troglitazone is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase enzyme in the ovary,” American Journal of Obstetrics & Gynecology, vol. 184, no. 4, pp. 575–579, 2001. View at Publisher · View at Google Scholar · View at PubMed
  17. J. D. Veldhuis, G. Zhang, and J. C. Garmey, “Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 3, pp. 1129–1133, 2002. View at Publisher · View at Google Scholar
  18. P. Kempná, G. Hofer, P. E. Mullis, and C. E. Flück, “Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2,” Molecular Pharmacology, vol. 71, no. 3, pp. 787–798, 2007. View at Publisher · View at Google Scholar · View at PubMed
  19. A. Dunaif, D. Scott, D. Finegood, B. Quintana, and R. Whitcomb, “The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 81, no. 9, pp. 3299–3306, 1996. View at Publisher · View at Google Scholar
  20. Y.-M. Mu, T. Yanase, Y. Nishi et al., “Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells,” Biochemical and Biophysical Research Communications, vol. 271, no. 3, pp. 710–713, 2000. View at Publisher · View at Google Scholar · View at PubMed
  21. C. E. Minge, R. L. Robker, and R. J. Norman, “PPAR gamma: coordinating metabolic and immune contributions to female fertility,” PPAR Research, vol. 2008, Article ID 243791, 19 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  22. C. Fürnsinn, P. Nowotny, B. Brunmair et al., “Thiazolidinediones influence plasma steroids of male obese Zucker rats,” Endocrinology, vol. 143, no. 1, pp. 327–330, 2002. View at Publisher · View at Google Scholar
  23. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 19–25, 2004. View at Publisher · View at Google Scholar
  24. A. Dunaif, “Adrenal disorders and polycystic ovary syndrome,” Hormone Research, vol. 37, pp. 39–44, 1992. View at Publisher · View at Google Scholar
  25. S. Franks, “Polycystic ovary syndrome,” The New England Journal of Medicine, vol. 333, no. 13, pp. 853–861, 1995. View at Google Scholar
  26. B. Toth, D. Hornung, C. Scholz, S. Djalali, K. Friese, and U. Jeschke, “Peroxisome proliferator-activated receptors: new players in the field of reproduction,” American Journal of Reproductive Immunology, vol. 58, no. 3, pp. 289–310, 2007. View at Publisher · View at Google Scholar · View at PubMed
  27. P. Froment, F. Gizard, D. Defever, B. Staels, J. Dupont, and P. Monget, “Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition,” Journal of Endocrinology, vol. 189, no. 2, pp. 199–209, 2006. View at Publisher · View at Google Scholar · View at PubMed
  28. A. Dunaif, “Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal,” Nature Reviews Endocrinology, vol. 4, no. 5, pp. 272–283, 2008. View at Publisher · View at Google Scholar · View at PubMed
  29. J. N. Feige, L. Gelman, D. Rossi et al., “The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor γ modulator that promotes adipogenesis,” The Journal of Biological Chemistry, vol. 282, no. 26, pp. 19152–19166, 2007. View at Publisher · View at Google Scholar · View at PubMed
  30. N. J. Barlow, S. L. Phillips, D. G. Wallace, M. Sar, K. W. Gaido, and P. M. D. Foster, “Quantitative changes in gene expression in fetal rat testes following exposure to di(n-butyl) phthalate,” Toxicological Sciences, vol. 73, no. 2, pp. 431–441, 2003. View at Publisher · View at Google Scholar · View at PubMed
  31. K. P. Lehmann, S. Phillips, M. Sar, P. M. D. Foster, and K. W. Gaido, “Dose-dependent alterations in gene expression and testosterone synthesis in the fetal testes of male rats exposed to di(n-butyl) phthalate,” Toxicological Sciences, vol. 81, no. 1, pp. 60–68, 2004. View at Publisher · View at Google Scholar · View at PubMed
  32. C. J. Thompson, S. M. Ross, and K. W. Gaido, “Di(n-butyl) phthalate impairs cholesterol transport and steroidogenesis in the fetal rat testis through a rapid and reversible mechanism,” Endocrinology, vol. 145, no. 3, pp. 1227–1237, 2004. View at Publisher · View at Google Scholar · View at PubMed
  33. J. Borch, M. Axelstad, A. M. Vinggaard, and M. Dalgaard, “Diisobutyl phthalate has comparable anti-androgenic effects to di-n-butyl phthalate in fetal rat testis,” Toxicology Letters, vol. 163, no. 3, pp. 183–190, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. J. Borch, S. B. Metzdorff, A. M. Vinggaard, L. Brokken, and M. Dalgaard, “Mechanisms underlying the anti-androgenic effects of diethylhexyl phthalate in fetal rat testis,” Toxicology, vol. 223, no. 1-2, pp. 144–155, 2006. View at Publisher · View at Google Scholar · View at PubMed
  35. M. M. Mansour, H. O. Goyal, T. D. Braden et al., “Activation of penile proadipogenic peroxisome proliferator-activated receptor γ with an estrogen: interaction with estrogen receptor alpha during postnatal development,” PPAR Research, vol. 2008, Article ID 651419, 10 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  36. J. Vandesompele, K. De Preter, F. Pattyn et al., “Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes,” Genome Biology, vol. 3, no. 7, article research0034.1-0034.11, pp. 1–12, 2002. View at Publisher · View at Google Scholar
  37. J. E. Caminos, R. Nogueiras, F. Gaytán et al., “Novel expression and direct effects of adiponectin in the rat testis,” Endocrinology, vol. 149, no. 7, pp. 3390–3402, 2008. View at Publisher · View at Google Scholar · View at PubMed
  38. M. Gurnell, “Peroxisome proliferator-activated receptor γ and the regulation of adipocyte function: lessons from human genetic studies,” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 19, no. 4, pp. 501–523, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar · View at PubMed
  40. O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996. View at Google Scholar
  41. N. Bhattacharya, J. M. Dufour, M.-N. Vo, J. Okita, R. Okita, and K. H. Kim, “Differential effects of phthalates on the testis and the liver,” Biology of Reproduction, vol. 72, no. 3, pp. 745–754, 2005. View at Publisher · View at Google Scholar · View at PubMed
  42. J. Y. Ryu, B. M. Lee, S. Kacew, and H. S. Kim, “Identification of differentially expressed genes in the testis of Sprague-Dawley rats treated with di(n-butyl) phthalate,” Toxicology, vol. 234, no. 1-2, pp. 103–112, 2007. View at Publisher · View at Google Scholar · View at PubMed
  43. S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4318–4323, 1997. View at Publisher · View at Google Scholar
  44. B. Shrilatha and Muralidhara, “Early oxidative stress in testis and epididymal sperm in streptozotocin-induced diabetic mice: its progression and genotoxic consequences,” Reproductive Toxicology, vol. 23, no. 4, pp. 578–587, 2007. View at Publisher · View at Google Scholar · View at PubMed
  45. J. B. Farrell, A. Deshmukh, and A. A. Baghaie, “Low testosterone and the association with type 2 diabetes,” The Diabetes Educator, vol. 34, no. 5, pp. 799–806, 2008. View at Publisher · View at Google Scholar · View at PubMed
  46. G. L. Hammond, “Extracellular steroidbinding proteins,” in Steroid Hormone Action, Frontiers in Molecular Biology, pp. 1–25, IRL Press at Oxford University, Oxford, UK, 1993. View at Google Scholar
  47. R. A. Young, R. Frink, and C. Longcope, “Serum testosterone and gonadotropins in the genetically obese male Zucker rat,” Endocrinology, vol. 111, no. 3, pp. 977–981, 1982. View at Google Scholar
  48. G. Berger, P. Bailey, C. Biswas et al., “Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice,” Endocrinology, vol. 137, no. 10, pp. 4189–4195, 1996. View at Publisher · View at Google Scholar
  49. T. M. Willson, J. E. Cobb, D. J. Cowan et al., “The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 665–668, 1996. View at Google Scholar